5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance
EJC SUPPLEMENTS（2009）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要